Production method for organoid
Patent Information
- Application Number
- JP2024506364
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Priority Date
- 2023-03-08
- Filing Date
- 2023-03-08
- Publication Date
- 2024-11-14
AI Technical Summary
Conventional cancer drug discovery methods using cancer cell lines fail to accurately predict drug efficacy and safety due to lack of representation of actual clinical tumors' genetic and biological diversity, and struggle to efficiently culture normal tissue-derived organoids for drug screening.
A method for producing and screening organoids involves dissociating biological tissues, culturing them in suspension medium without p38 inhibitors, and using a combination of extracellular matrix, IGF-1, FGF-2, Wnt agonists, BMP inhibitors, TGF-β inhibitors, and EGF to promote stable growth of both normal and tumor tissue-derived organoids, allowing for high-throughput drug screening with minimal side effects on normal tissues.
This approach enables efficient large-scale culture of organoids from both normal and tumor tissues, facilitating accurate drug screening with reduced side effects on normal tissues and enhanced efficacy on tumor tissues, thereby improving the drug discovery process.
Abstract
Description
How to make organoids
[0001] The present invention relates to a method for producing organoids. More specifically, the present invention relates to a method for producing organoids and a method for screening anticancer drugs. This application claims priority to US Provisional Application No. US63 / 317,552 filed on March 8, 2022, the contents of which are incorporated herein by reference.
[0002] Drug screening, which comprehensively explores the effects of numerous therapeutic drug candidates, is a fundamental technology in drug discovery. Conventional cancer drug discovery involves primary screening using cancer cell lines established from patient-derived cancer tissue, followed by confirmation of safety and side effects using animal models.
[0003] However, cancer cell lines often lack many of the characteristics of actual clinical tumors and their sensitivity to anticancer drugs. Furthermore, even cancers arising in the same organ exhibit different genetic and biological characteristics from patient to patient. It is difficult to capture this diversity using cancer cell lines. As a result, many anticancer drug candidates selected using cancer cell lines have not yet reached clinical application, and this "valley of death" in drug discovery research has become a major medical and social problem.
[0004] The inventors have pioneered the development of organoid technology for the permanent three-dimensional culture of tissue stem cells (see, for example, Non-Patent Documents 1 and 2). The inventors have also applied the organoid technology to various patient-derived cancer tissues, building cancer organoid biobanks for colon cancer, pancreatic cancer, gastric cancer, and other cancers (see, for example, Non-Patent Documents 3 to 5).
[0005] Patient-derived cancer organoids retain many of the characteristics of the patient's cancer tissue, and cancer organoid biobanks are expected to serve as next-generation cancer research resources and be applied to basic cancer research, cancer diagnostic tools, drug discovery, personalized treatment, and more.
[0006] Recent overseas clinical trials have shown that the drug sensitivity of patient-derived cancer organoids correlates with the response of clinical tumors to anticancer drugs, raising hopes for the implementation of organoid medicine, which uses organoids to predict the therapeutic effects of chemotherapy.
[0007] Sato T, et al., Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche, Nature, 459, 262-266, 2009.Sato T, et al., Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium, Gastroenterology, 141, 1762-1772, 2011.Fujii M, et al., A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis, Cell Stem Cell, 18, 827-838, 2016.Seino T, et al., Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression, Cell Stem Cell, 22, 454-467, 2018.Nanki K, et al., Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis, Cell, 174, 856-869, 2018.
[0008] However, conventional drug screening methods have difficulty evaluating side effects and safety on normal tissues. Normal tissues can be cultured using organoid technology. However, conventional culture techniques have made it difficult to efficiently mass-culture normal tissue-derived organoids. For this reason, normal tissue-derived organoids could not be used in drug screening.
[0009] Therefore, the present invention aims to provide a technique for efficiently mass-culturing organoids, regardless of whether they are derived from normal tissue or tumor tissue.
[0010] The present invention includes the following aspects: [1] A method for producing organoids, comprising the steps of dissociating a biological tissue and suspension-culturing the dissociated biological tissue in a dispersed state in a medium to form organoids, wherein the medium is substantially free of a p38 inhibitor and contains the following components (i) to (iv): (i) 0.1 to 10% by volume of extracellular matrix, (ii) insulin-like growth factor 1 (IGF-1), (iii) fibroblast growth factor 2 (FGF-2), and (iv) at least one selected from the group consisting of a Wnt agonist, a bone morphogenetic protein (BMP) inhibitor, a transforming growth factor-β (TGF-β) inhibitor, and an epidermal growth factor (EGF). [2] The production method according to [1], wherein the suspension culture is carried out while stirring the medium. [3] The manufacturing method according to [1] or [2], wherein the biological tissue is normal tissue. [4] The manufacturing method according to any one of [1] to [3], wherein the Wnt agonist is at least one selected from the group consisting of a Wnt protein, R-spondin, and a GSK-3β inhibitor. [5] The manufacturing method according to any one of [1] to [4], wherein the Wnt agonist is a Wnt protein and R-spondin. [6] The manufacturing method according to [5], wherein the Wnt protein is a complex with afamin. [7] A method for screening anticancer drugs, comprising the steps of: culturing normal tissue-derived organoids and tumor tissue-derived organoids in a suspension culture medium in the presence of a test substance; and evaluating the effects of the test substance on the normal tissue-derived organoids and the tumor tissue-derived organoids, wherein a test substance that has few side effects on the normal tissue-derived organoids and is effective on tumor tissue-derived organoids is an anticancer drug that is effective on the tumor tissue, and the culture medium is substantially free of p38 inhibitors and contains the following components (i) to (iv):(i) 0.1 to 10% by volume of extracellular matrix; (ii) IGF-1; (iii) FGF-2; and (iv) at least one selected from the group consisting of a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and an EGF. [8] The screening method described in [7], wherein the normal tissue-derived organoid is an organoid produced by the production method described in [3].
[0011] According to the present invention, a technique for efficiently mass-culturing organoids can be provided, regardless of whether they are derived from normal tissue or tumor tissue.
[0012] FIG. 1 is a graph showing the results of measuring organoid proliferation in Experimental Example 1. FIG. 2 is a graph showing the results of calculating the organoid doubling time in Experimental Example 1. FIG. 3 is a graph showing the results of measuring organoid proliferation in Experimental Example 2. FIG. 4 is a graph showing the results of calculating the coefficient of variation of the fluorescent dye area in Experimental Example 2. FIG. 5 is a graph showing the results of calculating the Z'-factor for each organoid in Experimental Example 2. FIG. 6 is a diagram showing the results of all drug-organoid combinations in the high-throughput screening (HTS) performed in Experimental Example 2. FIG. 7 is a graph showing the distribution of Z'-factors in 237 screening plates in Experimental Example 3. FIG. 8 is a graph showing the root mean square error (rms) of the sigmoid response curve fitted to the dose-response curve in Experimental Example 3. FIG. 9 shows the logarithm of the effects of 56 drugs on normal colon organoid lines (NLCRC15) obtained in triplicate in Experimental Example 3. 2 (IC 50 10 is a graph showing the results of comparing IC 50 11 is a volcano plot showing the results of multivariate analysis of variance (MANOVA) in Experimental Example 4. FIG. 12 is a graph showing the IC of (+)-JQ1 for normal colon organoids (n=6) and CRC organoids (n=15) measured in Experimental Example 4. 5013 is a graph showing the response of normal colon organoids and CRC organoids to (+)-JQ1, obtained in Experimental Example 4. The scale bar is 500 μm.
[0013] [Method for producing organoids] In one embodiment, the present invention provides a method for producing organoids, comprising the steps of dissociating a biological tissue and suspension-culturing the dissociated biological tissue in a dispersed state in a medium, thereby forming organoids, wherein the medium is substantially free of a p38 inhibitor and contains the following components (i) to (iv): (i) 0.1 to 10% by volume of an extracellular matrix, (ii) IGF-1, (iii) FGF-2, and (iv) at least one selected from the group consisting of a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and EGF.
[0014] As will be described later in the Examples, the method of this embodiment allows stable mass culture of normal tissue-derived organoids, making it possible to mass-produce normal tissue-derived organoids. The method of this embodiment can also be called a method of culturing organoids. In this embodiment, mass culture refers to, for example, culturing 10 6 ~10 7 This means growing organoids of cells.
[0015] In the manufacturing method of this embodiment, living tissue can be the living tissue derived from patient, or can be the organoid that has already been established.When living tissue is organoid, the manufacturing method of this embodiment can also be called the method of subculturing organoid.
[0016] In the manufacturing method of this embodiment, the biological tissue is preferably epithelial tissue. Examples of epithelial tissue include intestinal epithelial tissue. The intestine is the organ in the human body with the largest surface area in contact with the outside world, and performs functions essential for maintaining life, such as digestion and absorption. Most intestinal functions are carried out by the intestinal epithelium that covers its inner layer. The intestinal epithelium is composed of two compartments: villi composed of three lineages of differentiated cells (mucous-producing cells, absorptive epithelial cells, and endocrine cells), and crypts composed mainly of undifferentiated proliferative cells. The epithelial tissue is preferably epithelial stem cells or tissue containing epithelial cells. Epithelial cells include differentiated epithelial cells and epithelial stem cells. "Epithelial stem cells" refer to cells that have long-term self-renewal ability and the ability to differentiate into epithelial differentiated cells, and refer to stem cells derived from epithelial tissue. Examples of epithelial tissues include tissues of the cornea, oral mucosa, skin, conjunctiva, bladder, renal tubules, kidneys, digestive organs (esophagus, stomach, duodenum, small intestine (including jejunum and ileum), large intestine (including colon)), liver, pancreas, mammary gland, salivary gland, lacrimal gland, prostate, hair root, trachea, lung, etc.
[0017] The biological tissue is preferably tissue derived from a human or a non-human mammal. Non-human mammals are not particularly limited, and examples thereof include mice, rats, cows, pigs, rabbits, and monkeys. In the production method of this embodiment, the biological tissue may be tumor tissue or cancer tissue, or may be normal tissue. Here, tumor tissue means tumorigenic tissue, and cancer tissue means cancerous tissue.
[0018] Dissociating biological tissue means fragmenting the biological tissue and dividing it into cell clusters of one to several cells. Here, several cells may mean approximately two to 100 cells. Dissociation of biological tissue may be performed by mechanical shearing or by enzymatic treatment with collagenase, dispase I, liberase, trypsin, TrypLE Express (Thermo Fisher Scientific), or the like.
[0019] It is known that organoids may recover poorly after dissociation into single cells. In response to this, the inventors have discovered that a p38 inhibitor, which has recently been considered essential for culturing human intestinal organoids, inhibits the growth of organoids from single cells. The inventors further found that replacing the p38 inhibitor with a combination of IGF-1 and FGF-2 promotes the growth of organoids from single cells.
[0020] In addition, conventional general organoid culture protocols include a step of embedding dissociated organoids in an extracellular matrix such as Matrigel (registered trademark). However, organoids embedded in an extracellular matrix may be difficult to expand in culture scale. Furthermore, organoids embedded in an extracellular matrix may exhibit large variations when grown.
[0021] In contrast, in the production method of this embodiment, dissociated biological tissue is cultured in suspension in a state where it is dispersed in a medium. That is, in the production method of this embodiment, the dissociated biological tissue is not embedded in an extracellular matrix, but is cultured in suspension in a state where the cells are dispersed in a medium containing the extracellular matrix.
[0022] As described later in the examples, the manufacturing method of this embodiment can stably culture not only cancer organoids but also normal tissue-derived organoids in large quantities. Furthermore, by accurately aligning the number of cells when seeding cells, it is possible to suppress the variation in the number of cells between wells. To align the number of cells, for example, sorting by a cell sorter can be used.
[0023] Examples of p38 inhibitors that have been used in conventional organoid culture include SB202190 (CAS number: 152121-30-7), SB203580 (CAS number: 152121-47-6), VX-702 (CAS number: 745833-23-2), VX-745 (CAS number: 209410-46-8), PD169316 (CAS number: 152121-53-4), RO4402257 (CAS number: 1449811-01-2), and BIRB796 (CAS number: 285983-48-4).
[0024] In contrast, the production method of this embodiment uses a medium that is substantially free of p38 inhibitors. As used herein, the term "substantially free of p38 inhibitors" means that no p38 inhibitors are intentionally added to the medium, and that the unavoidable inclusion of p38 inhibitors is acceptable as long as the effects of this embodiment are achieved.
[0025] The medium used in the production method of this embodiment contains an extracellular matrix. The extracellular matrix is a non-cellular component that includes various polysaccharides, water, elastin, and glycoproteins. Examples of glycoproteins include collagen, entactin (nidogen), fibronectin, and laminin.
[0026] Commercially available extracellular matrices may be used, such as extracellular matrix proteins (Thermo Fisher Scientific), basement membrane preparations derived from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells (e.g., Matrigel (registered trademark), Corning), and ProNectin (Sigma-Aldrich).
[0027] The medium used in the production method of this embodiment preferably contains 0.1 to 10% by volume, for example 0.1 to 5% by volume, for example 0.1 to 3% by volume, for example about 2% by volume, of extracellular matrix.
[0028] The medium used in the production method of this embodiment contains IGF-1. IGF-1, also known as somatomedin C, is a factor secreted mainly in the liver in response to stimulation by growth hormone (GH). The concentration of IGF-1 contained in the medium may be, for example, 5 ng / mL to 1 μg / mL, for example, 10 ng / mL to 1 μg / mL, or for example, 50 to 500 ng / mL.
[0029] The medium used in the production method of this embodiment contains FGF-2. FGF-2 is a basic fibroblast growth factor, also known as bFGF. The concentration of FGF-2 contained in the medium may be, for example, 5 ng / mL to 1 μg / mL, for example, 10 ng / mL to 1 μg / mL, or for example, 50 to 500 ng / mL.
[0030] As described in the Examples below, replacing the p38 inhibitor, which was previously considered essential for organoid culture, with a combination of IGF-1 and FGF-2 promotes the growth of organoids from single cells. As a result, not only cancer organoids but also organoids derived from normal tissues can be stably cultured in large quantities.
[0031] The medium used in the production method of this embodiment contains at least one selected from the group consisting of a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and EGF. The medium used in the production method of this embodiment may contain two selected from the group consisting of a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and EGF, or may contain three selected from the group consisting of a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and EGF, or may contain a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and EGF.
[0032] A Wnt agonist refers to a substance that activates T-cell factor (hereinafter sometimes referred to as "TCF") / lymphoid enhancer factor (hereinafter sometimes referred to as "LEF")-mediated transcription within cells. Wnt agonists are not limited to Wnt family proteins, but also include agonists that bind to and activate Frizzled receptor family members, inhibitors of intracellular β-catenin degradation, and TCF / LEF activators.
[0033] The Wnt agonist is preferably at least one selected from the group consisting of a Wnt protein, R-spondin, and a GSK-3β inhibitor.
[0034] A Wnt agonist is a substance that stimulates Wnt activity in a cell by at least 10%, preferably at least 20%, more preferably at least 30%, even more preferably at least 50%, particularly preferably at least 90%, and most preferably 100%, compared to the level of Wnt activity in the absence of the Wnt agonist. Wnt activity can be assessed, for example, by measuring the transcriptional activity of Wnt using a TCF reporter assay.
[0035] The Wnt agonist is preferably a combination of a Wnt protein and R-spondin. The origin of the Wnt protein is not particularly limited, and Wnt proteins derived from various organisms can be used. Among these, a Wnt protein derived from a mammal is preferred. The mammals are the same as those described above. Examples of mammalian Wnt proteins include Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, and Wnt16. One type of Wnt protein may be used alone, or two or more types may be used in combination.
[0036] The Wnt protein may be prepared using Wnt protein-expressing cells or may be commercially available. As long as it has Wnt activity, the Wnt protein may be a fragment of a Wnt protein or may contain an amino acid sequence other than that of a Wnt protein. Examples of amino acid sequences other than that of a Wnt protein include the amino acid sequence of an affinity tag. Furthermore, the amino acid sequence of a Wnt protein does not need to be completely identical to an amino acid sequence obtainable from a publicly known database such as GenBank. As long as it has Wnt activity, it may be an amino acid sequence obtainable from a publicly known database in which one to several amino acids have been deleted, substituted, or added. Here, "one to several" preferably refers to 10 or fewer amino acids, more preferably 7 or fewer amino acids, and even more preferably 6 or fewer amino acids.
[0037] The concentration of the Wnt protein contained in the culture medium may be, for example, 50 ng / mL to 10 μg / mL, for example, 100 ng / mL to 10 μg / mL, for example, 200 ng / mL to 1 μg / mL, or for example, 300 ng / mL to 1 μg / mL.
[0038] Preferably, the Wnt protein forms a complex with afamin. Afamin is a glycoprotein belonging to the albumin family and is known to be present in body fluids such as blood. The serum added to the cell culture medium contains afamin derived from the animal from which the serum was collected. Because serum contains impurities other than afamin, it is preferable to use afamin alone without using serum.
[0039] The origin of afamin is not particularly limited, and afamin derived from various organisms can be used. Among these, afamin derived from mammals is preferred. Mammals are the same as those described above.
[0040] Afamin may be a natural afamin contained in serum or the like purified by a known method, or it may be recombinant afamin. Recombinant afamin can be produced by appropriately using known genetic recombination techniques. Recombinant afamin can be produced, for example, by inserting DNA encoding afamin into a known expression vector, introducing the resulting expression vector into an appropriate host cell to express the recombinant afamin, and purifying it by a known purification method.
[0041] The recombinant afamin may be an afamin to which an affinity tag has been added. The affinity tag to be added is not particularly limited, and can be appropriately selected from known affinity tags. The affinity tag is preferably an affinity tag that can be recognized by a specific antibody, and examples include a FLAG tag, a MYC tag, an HA tag, and a V5 tag.
[0042] The above-mentioned Wnt proteins have strong hydrophobicity due to modification of specific serine residues with a fatty acid (palmitoleic acid). Therefore, it is widely known that Wnt proteins are prone to aggregation or denaturation in aqueous solution, making purification and storage extremely difficult. However, it has been reported that modification of this specific serine residue with a fatty acid is essential for the physiological activity of Wnt proteins and is involved in binding to Frizzled receptor family members.
[0043] In aqueous solution, Wnt proteins bind one-to-one with afamin to form a complex, allowing them to be solubilized while maintaining high physiological activity. Thus, Wnt protein-afamin complexes can be produced by culturing cells that express both Wnt proteins and afamin, or by co-culturing Wnt protein-expressing cells and afamin-expressing cells. The Wnt protein-afamin complex can also be added to culture media in the form of a conditioned medium.
[0044] The concentration of afamin contained in the medium may be, for example, 50 ng / mL to 10 μg / mL, for example, 100 ng / mL to 10 μg / mL, for example, 200 ng / mL to 1 μg / mL, or for example, 300 ng / mL to 1 μg / mL.
[0045] Examples of R-spondins include the R-spondin family consisting of R-spondin1, R-spondin2, R-spondin3, and R-spondin4. The R-spondin family is a secreted protein known to be involved in the activation and regulation of the Wnt signaling pathway. As R-spondin, a fragment of R-spondin may be used, or one containing an amino acid sequence other than the amino acid sequence of R-spondin, such as an affinity tag, as long as it has R-spondin activity. One type of R-spondin may be used alone, or two or more types may be used in combination.
[0046] The concentration of R-spondin contained in the medium may be, for example, 50 ng / mL to 10 μg / mL, for example, 100 ng / mL to 10 μg / mL, for example, 200 ng / mL to 1 μg / mL, or for example, 300 ng / mL to 1 μg / mL. R-spondin may be added to the medium in the form of a conditioned medium.
[0047] Examples of GSK-3β inhibitors include CHIR99021 (CAS number: 252917-06-9), Kenpaullone (CAS number: 142273-20-9), and 6-bromoindirubin-3′-oxime (BIO, CAS number: 667463-62-9).
[0048] Examples of BMP inhibitors include substances that have an inhibitory activity of preferably 50% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more, compared to the BMP activity level in the absence of the inhibitor. BMP inhibitory activity can be evaluated by measuring the transcription activity of BMP.
[0049] The BMP inhibitor is preferably a natural BMP-binding protein, and examples thereof include chordin-like proteins such as noggin, gremlin, chordin, and chordin domain; follistatin-related proteins such as follistatin and follistatin domain; DAN-like proteins such as differential screening-selected gene aberrative in neuroblastoma (DAN) and DAN cysteine-knot domain; sclerostin (SOST); decorin; and α-2 macroglobulin.
[0050] The concentration of the BMP inhibitor contained in the culture medium may be, for example, 10 ng / mL to 1 μg / mL, for example, 20 ng / mL to 1 μg / mL, for example, 50 ng / mL to 1 μg / mL, or for example, about 100 ng / mL.
[0051] TGF-β is a type of growth factor that is produced by almost all cells, including those in the kidney, bone marrow, and platelets. There are five subtypes of TGF-β (β1 to β5). TGF-β is known to promote the proliferation of osteoblasts and the synthesis and proliferation of connective tissues such as collagen, while suppressing the proliferation of epithelial cells and osteoclasts. Generally, a TGF-β inhibitor is, for example, a drug that blocks or inhibits the binding of TGF-β to a TGF-β receptor, and binds to TGF-β to form a complex that neutralizes TGF-β activity. A TGF-β inhibitor is, for example, a drug that binds to a TGF-β receptor and blocks or inhibits the binding of TGF-β to the receptor, acting as an antagonist or inverse agonist.
[0052] Examples of TGF-β inhibitors include substances that have an inhibitory activity of preferably 50% or more, more preferably 70% or more, even more preferably 80% or more, and particularly preferably 90% or more, compared to the TGF-β activity level in the absence of the inhibitor.
[0053] Examples of TGF-β inhibitors include A83-01 (CAS number: 909910-43-6), SB431542 (CAS number: 301836-41-9), SB505124 (CAS number: 694433-59-5), SB525334 (CAS number: 356559-20-1), LY364947 (CAS number: 396129-53-6), SD208 (CAS number: 627536-09-8), and SJN2511 (CAS number: 446859-33-2). Among these, A83-01 is preferred.
[0054] The concentration of the TGF-β inhibitor contained in the culture medium may be, for example, 100 nM to 1 μM, for example, 200 nM to 1 μM, for example, 300 nM to 1 μM, or for example, about 500 nM.
[0055] In the production method of this embodiment, the medium may contain a mitogenic growth factor in addition to the above-mentioned components. Examples of mitogenic growth factors include epidermal growth factor (EGF), transforming growth factor-α (TGF-α), and keratinocyte growth factor (KGF). These mitogenic growth factors may be used alone or in combination of two or more.
[0056] EGF is a potent mitogen for a variety of cultured ectodermal and mesodermal cells and has a profound effect on the differentiation of specific cells, including some fibroblasts. The EGF precursor exists as a membrane-bound molecule that is proteolytically cleaved to generate a 53-amino acid peptide hormone that stimulates cells.
[0057] Among mitogenic growth factors, EGF is preferred. The concentration of EGF contained in the medium may be, for example, 5 to 500 ng / mL, for example, 10 to 400 ng / mL, or for example, about 50 ng / mL.
[0058] In the manufacturing method of this embodiment, preferably, the suspension culture of dissociated biological tissue is carried out while stirring the medium.As will be described later in the examples, the suspension stirring culture can make organoids grow more rapidly than the suspension culture.
[0059] [Method for screening anticancer agents] In one embodiment, the present invention provides a method for screening anticancer agents, comprising the steps of: culturing normal tissue-derived organoids and tumor tissue-derived organoids in a suspension culture medium in the presence of a test substance; and evaluating the effects of the test substance on the normal tissue-derived organoids and tumor tissue-derived organoids, wherein a test substance that has few side effects on the normal tissue-derived organoids and is effective on the tumor tissue-derived organoids is indicated to be an anticancer agent effective on the tumor tissue, and the medium is substantially free of p38 inhibitors and contains the following components (i) to (iv): (i) 0.1 to 10% by volume of extracellular matrix, (ii) IGF-1, (iii) FGF-2, and (iv) at least one selected from the group consisting of a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and EGF.
[0060] Previously, it was difficult to stably culture large amounts of normal tissue-derived organoids, making it impossible to incorporate them into drug screening, which made it difficult to evaluate the side effects and safety of drugs on normal tissues.
[0061] On the other hand, as described later in Examples, the screening method of this embodiment can be used to screen drugs that are derived from normal tissues together with tumor tissue-derived organoids.As a result, it is possible to evaluate the side effects and safety of drugs on normal tissues.In addition, as described later in Examples, it is possible to screen drugs that specifically suppress the growth of tumor tissue-derived organoids without affecting the growth of normal tissue-derived organoids.
[0062] As described later in the Examples, by accurately aligning the number of cells when seeding organoids, it is possible to suppress variations in the number of cells between wells. To align the number of cells, for example, sorting using a cell sorter can be used.
[0063] In the screening method of this embodiment, the test substance is not particularly limited, and for example, a natural compound library, a synthetic compound library, an existing drug library, etc. The screening method of this embodiment enables high-throughput screening (HTS) with high accuracy, robustness, and reproducibility.
[0064] In the screening method of this embodiment, the normal tissue-derived organoid is preferably an organoid produced by the above-mentioned production method. In the screening method of this embodiment, the extracellular matrix, IGF-1, FGF-2, Wnt agonist, BMP inhibitor, TGF-β inhibitor, EGF, organoid, etc. are the same as those described above.
[0065] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.
[0066] Materials and Methods: (Establishment of Patient-Derived Organoids) Seven newly established organoid lines and patient-derived organoid lines established in previous studies were used. All samples used for organoid establishment and biological analysis were obtained from Keio University Hospital or the University of Tokyo Hospital with written informed consent. This study was approved by the ethics committees of both institutions.
[0067] Normal and neoplastic colon tissues were obtained from either endoscopic biopsies or surgically resected specimens. Samples were stored in ice-cold phosphate-buffered saline (PBS) until processing. Fresh tissue samples were cut into small pieces, washed at least 10 times with ice-cold PBS, and then digested with Liberase (TH grade, Roche) at 37°C for 60 minutes with vigorous pipetting every 15 minutes. The remaining fragments were further treated with TrypLE Express (Thermo Fisher Scientific) at 37°C for 20 minutes. The supernatant was then collected and centrifuged at 200 × g for 3 minutes at 4°C. The cell pellet was then suspended in Matrigel® (growth factor-reduced, BD Biosciences) and dispensed into a 48-well culture plate (25 μL of Matrigel® per well). The name of each organoid strain used and the properties of the tissue from which each organoid was derived are shown in Table 1 below. In Table 1, in the "histology" column, "NL" indicates normal tissue, "TA" indicates tubular adenoma, "SSL" indicates serrated lesion, "well" indicates well-differentiated adenocarcinoma, "mod" indicates moderately differentiated adenocarcinoma, "por" indicates poorly differentiated adenocarcinoma, and "muc" indicates mucinous adenocarcinoma. In addition, in the "location" column, "A" indicates the ascending colon, "T" indicates the transverse colon, "D" indicates the descending colon, "S" indicates the sigmoid colon, "R" indicates the rectum, "LM" indicates liver metastasis, and "C" indicates the cecum. In addition, in the "gender" column, "F" indicates female, and "M" indicates male. In addition, in the "Culture Conditions" column, "W" indicates Wnt, "E" indicates EGF, "N" indicates Noggin, "R" indicates R-Spondin1, "A" indicates A83-01, "S" indicates SB202190, and "-" indicates that no growth factor is required.
[0068]
[0069] (Organoid Culture) Human colorectal cancer (CRC) organoids were cultured in a medium containing 2% by volume of Matrigel® (Corning). The medium used was a basal medium supplemented with various combinations of growth factors depending on whether the organoids were derived from normal tissue or tumor tissue, and, if derived from tumor tissue, the tumor origin. The medium was agitated using an Orbital Shaker MaxQ 2000 CO2 plus, CO2 2 Resistance (Thermo Fisher Scientific) was used.
[0070] The basal medium used was advanced DMEM / F12 supplemented with penicillin / streptomycin, 10 mM HEPES, 2 mM GlutaMAX, 1x B27 (Thermo Fisher Scientific), 10 nM gastrin I (Sigma-Aldrich), and 1 mM N-acetylcysteine (Fujifilm Wako Pure Chemical Industries).
[0071] Normal tissue-derived organoids were maintained in improved medium or conventional medium. The improved medium was a basal medium supplemented with the following seven growth factors: 20% Afamin-Wnt3A serum-free conditioned medium, 10% R-spondin-1 conditioned medium, 50 ng / mL mouse recombinant EGF (Thermo Fisher Scientific), 500 nM A83-01 (Tocris), 100 ng / mL mouse recombinant Noggin (Peprotech), 100 ng / mL recombinant human IGF-1 (Biolegend), and 50 ng / mL recombinant human FGF-basic (FGF-2) (Peprotech).
[0072] The conventional medium was the same as the improved medium, except that 10 μM SB202190 (Sigma-Aldrich) was added instead of IGF-1 and FGF-2. Some growth factors were not required in tumor organoids due to genetic mutations.
[0073] Organoids were collected, washed, and fragmented by mechanical shearing or digestion with TrypLE Express (Thermo Fisher Scientific). After passage, the organoid fragments were cultured in fresh medium containing 10 μM Y-27632 (Fujifilm Wako Pure Chemical Industries) for two days to prevent cell death.
[0074] (Drug Screening Assay) The Standard Inhibitor Kit (SCADS Inhibitor Kit) drug library was provided by the Anticancer Drug Screening Committee, Cancer Research Support Project, Grant-in-Aid for Scientific Research on Innovative Areas, Ministry of Education, Culture, Sports, Science and Technology.
[0075] A total of 23 organoid lines were screened in this study. Prior to screening, organoids were labeled with green fluorescent protein (GFP) using the PB-CMV-MCS-EF1α-GFP-Puro PiggyBac (PB513B-1, System Biosciences) and Super PiggyBac transposase (PB210-20, System Biosciences) vectors.
[0076] Organoids were dissociated using TrypLE Express (Thermo Fisher Scientific) and filtered through a 20-μm pore-size cell strainer (Sysmex). 800–1,500 cells were sorted into each well of a 384-well plate using a cell sorter (SH800, Sony).
[0077] Organoids were treated with test compounds 24 or 96 hours after seeding. Organoids were grown for 6-8 days, and colony area was measured based on GFP fluorescence using an IN Cell Analyzer 6000 confocal imaging system (GE Healthcare Life Sciences). Bright-field imaging and luminescence-based ATP measurements were also performed using a Cell3iMager duos (SCREEN) and CellTiter-Glo cell viability assay (Promega).
[0078] Brightfield images were analyzed using Cell3iMager software. Default parameters were used for preprocessing and object detection, and supervised live / dead detection was applied for machine learning. For the (+)-JQ1 assay, cell viability was determined using the CellTiter-Glo Cell Viability Assay (Promega).
[0079] Dose-Response Curve Fitting: A Bayesian sigmoidal model was used to fit dose-response curves to the drug response data. Drug response data were acquired in triplicate, including at least six no-drug controls and seven drug responses at two-fold concentrations. In all screening plates, the proteasome inhibitor MG-132 was tested at a maximum concentration of 1 μM to ensure 100% cell death and accurate estimation of background signal.
[0080] A four-parameter sigmoidal response curve was fitted as follows: First, organoid viability was normalized by dividing it by the mean of drug-free controls. Organoid viability X lc was estimated to be the average value of the following formula (1): lc =I min + (I max -I min ) / (1+e(lc-βpos) / βshape))...(1) In formula (1), I max represents the survival rate of the drug-free control, and I min represents the average background signal, β represents the position of the sigmoid curve, β represents the steepness, and lc represents the log concentration.
[0081] Organoid viability X lc variance Var(X lc ) = BE(X lc ) is assumed to have a gamma distribution, where B represents the noise parameter. The survival rate of the drug-free control, X max Also, the variance Var(X max ) = BI max It is assumed that there is a gamma distribution of
[0082] Markov chain Monte Carlo simulations were performed using rstan (v.2.18.0) to estimate the parameters. Initial values were randomly generated from the prior distribution. Following 1,000 burn-in iterations, 1,000 iterations were sampled from four independent chains to obtain the posterior distribution. The median of the posterior distribution was used as the parameter estimate. βpos had a normal prior distribution with a 99% probability mass, covering a range from 1 / 100th the minimum concentration tested to 100 times the maximum tested concentration. I max had a uniform prior distribution between 0 and 5. min I min = αI max (where α has a uniform prior distribution between 0 and 1). B and β shapes had low-informative priors (semi-Cauchy distributions with location = 0 and scale = 10). If the R convergence metric was > 1.1 or the mean absolute error > 0.3, the curve fit was deemed insufficient and discarded, and no downstream analysis was performed.
[0083] AUC values were estimated using a trapezoidal approximation. AUC values are plotted against the concentration range tested and the I in the vertical direction. max and I min The area is determined as part of a rectangle that covers the area enclosed by the
[0084] [Experimental Example 1] (Suspension culture of organoid) Human colorectal cancer (CRC) organoid was cultured in suspension in the medium containing 2% by volume of Matrigel (registered trademark), and its proliferation was examined.For comparison, the conventional culture method, embedded in Matrigel (registered trademark) droplet culture, was also carried out.In addition, the organoid was cultured in suspension and the medium was stirred, and the suspension stirring culture was also carried out.
[0085] Figure 1 is a graph showing the results of measuring organoid proliferation under each culture condition (n = 3). In Figure 1, "CRC17b," "CRC25a," "CRC32," and "NLCRC32" are the names of organoid strains. The properties of each organoid strain are shown in Table 1 above. CRC17b, CRC25a, and CRC32 are CRC organoids, and NLCRC32 is an organoid derived from normal tissue. As a result, for all organoids, when cultured in suspension, they proliferated more rapidly than when cultured in droplets of Matrigel (registered trademark). 6 ~10 7 The results showed that organoids proliferated to the same extent as cells. Furthermore, organoids proliferated even more rapidly when cultured in agitated suspension.
[0086] Figure 2 is a graph showing the results of calculating the doubling time of organoids under each culture condition. As a result, compared to cultures embedded in Matrigel (registered trademark) droplets, suspension culture tended to have a shorter doubling time, and suspension agitation culture tended to have an even shorter doubling time.
[0087] Example 2: Robust High-Throughput Screening (HTS) System for Patient-Derived Colorectal Organoids Non-uniform dissociation of organoids, especially when organoids are dissociated by mechanical shearing, can result in selective organoid growth from large organoid fragments and variability in organoid growth between wells.
[0088] To ensure accurate distribution of viable single cells per culture well, organoids were labeled with GFP and sorted into individual wells of a 384-well plate by flow cytometry. Fluorescently labeled organoids also enabled automated imaging and measurement of organoid proliferation using a high-content cell image analyzer.
[0089] A drug library containing 56 drugs was used to analyze the drug sensitivity of CRC organoids and normal colon organoids to each drug. The drug library included nine clinically used anticancer drugs and 47 small molecule inhibitors targeting cancer-related signaling pathways. Of the organoid strains listed in Table 1 above, six normal colon organoid strains and 20 CRC organoid strains were subjected to HTS. HTS was performed on a total of 1,438 drug-organoid combinations using 237 screening plates.
[0090] Drugs from the drug library were added 4 days after cell seeding, and organoid proliferation was calculated based on the area of the fluorescent dye. To confirm that this method is comparable to other methods, organoid viability was also analyzed using an ATP-based luminescence assay and bright-field imaging analysis.
[0091] Fluorescence measurements and ATP-based luminescence assays showed similar results for many drugs. Bright-field imaging analysis also produced similar results to ATP-based luminescence assays. However, due to differences in morphology between CRC organoids, determining cell viability using bright-field imaging analysis required post-hoc parameter calibration for each organoid strain. Therefore, determining cell viability using bright-field imaging analysis tends to impair the ease of screening and reduce throughput.
[0092] HTS using normal human colon organoids has traditionally been difficult due to poor recovery of the organoids after dissociation into single cells. In response, the inventors have recently discovered that a p38 inhibitor, which has been considered essential for culturing human intestinal organoids, inhibits the growth of organoids from single cells. The inventors have also found that replacing the p38 inhibitor with a combination of IGF-1 and FGF-2 promotes the growth of organoids from single cells.
[0093] Organoids were cultured in either conventional medium containing a p38 inhibitor (SB202190) or modified medium containing IGF-1 and FGF-2 instead of the p38 inhibitor, and their proliferation was measured based on the area of fluorescent dye. 800 cells were sorted and cultured in 384-well plates.
[0094] Figure 3 is a graph showing the results of measuring organoid proliferation. The left side of Figure 3 shows the results for normal colon organoids, and the right side of Figure 3 shows the results for CRC organoids. In Figure 3, each dot represents the measurement result for one well. The bars in the graph represent the mean ± standard deviation. In Figure 3, "*" indicates P = 9.51 × 10 -13 (NLCRC32 strain, n = 22 wells), P = 1.12 × 10 -21 (CRC24b strain, n = 44 wells), P = 4.52 × 10 -21 (CRC31 strain, n=36 wells) indicates a significant difference.
[0095] Figure 4 is a graph showing the results of calculating the coefficient of variation of the fluorescent dye area. The left side of Figure 4 shows the results for normal colon organoids, and the right side of Figure 4 shows the results for CRC organoids. In Figure 4, "*" indicates P = 7.28 × 10 -8 (NLCRC32 strain, n = 22 wells), P = 5.69 × 10 -5 (CRC24b strain, n = 44 wells), P = 3.95 × 10 -2 (CRC31 strain, n=36 wells) indicates a significant difference.
[0096] Figure 5 shows the calculated Z'-factor for each organoid. The results demonstrate that the application of the improved medium not only improved the organoid culture efficiency, but also enabled the uniform culture of even single-cell sorted normal colon organoids. Furthermore, the Z'-factor, which was higher than 0.5, demonstrated that this screening system is a high-quality HTS system.
[0097] The above results demonstrate that the HTS system of this experimental example can be used to perform drug screening on various organoids, including organoids derived from normal tissue.
[0098] [Experimental Example 3] (Summary of drug responses in colorectal organoids) Figure 6 shows the results of all drug-organoid combinations in the HTS performed in Experimental Example 2. In Figure 6, the drug responses are expressed as log 2 (IC 50 ) Z-scores are shown. For some drugs, molecular targets are shown. In HTS, 82% of the screening plates had a Z'-factor greater than 0.5.
[0099] Figure 7 is a graph showing the distribution of Z'-factors in 237 screening plates. Normal colon organoids were seeded on 58 screening plates, and CRC organoids were seeded on 139 screening plates. As shown in Figure 7, no significant difference in Z'-factor was observed between normal colon organoids and CRC organoids.
[0100] Each drug response is expressed as a 50% inhibitory concentration (IC 50 The results were summarized as the dose-response curve steepness, the area under the dose-response curve, and the root mean square error (rms) of the sigmoidal response curve fitted to the dose-response curve. Figure 8 shows the root mean square error (rms) of the sigmoidal response curve fitted to the dose-response curve. The mean rms error was 0.119, indicating the robustness of the curve fitting.
[0101] Figure 9 shows the logarithm of 56 drugs on a normal colon organoid line (NLCRC15) obtained in triplicate. 2 (IC 50 ) across repeated experiments. As a result, it was confirmed that the results of three independent assays showed a high correlation.
[0102] The above results demonstrate that the HTS system of Experimental Example 2 has high accuracy, robustness, and reproducibility.
[0103] FIG. 10 is an IC 50 10 is a graph showing the results of calculating Spearman's correlation coefficients for all pairs of organoid strains based on the values of . In Figure 10, each dot represents one pair of organoid strains. The bars in the graph represent the mean ± standard deviation. In addition, "*" indicates P = 1.34 × 10 -6indicates a significant difference, and "**" indicates P = 3.61 × 10 -7 "Normal-Normal" indicates the results of a pair of normal colon organoid lines (n = 15), "Normal-CRC" indicates the results of a pair of normal colon organoid lines and CRC organoid lines (n = 120), and "CRC-CRC" indicates the results of a pair of CRC organoid lines (n = 190).
[0104] As a result, the six normal colon organoid lines showed comparable drug responses. In contrast, the drug responses varied significantly among the CRC organoid lines. Although the drug responses varied significantly among the CRC organoid lines, as shown in Figure 6, the CRC organoids showed similar responses to drugs that share the same targets, such as EGFR inhibitors, mTOR inhibitors, and topoisomerase inhibitors.
[0105] These results suggest that the heterogeneity in drug response of CRC organoids is not due to technical issues, but rather to genetic or epigenetic diversity of CRC organoids.
[0106] [Experimental Example 4] (Bromodomain and extra-terminal motif (BET) bromodomain protein inhibitors suppressed CRC growth) Based on the results of the HTS performed in Experimental Example 2, the drug responses of normal colon organoids and CRC organoids were compared using multivariate analysis of variance (MANOVA).
[0107] Figure 11 shows a volcano plot of the MANOVA results. Each dot in Figure 11 represents one drug. Shaded dots indicate drugs with statistically significant differences. Over 60% of the drugs (36 / 56, 64.3%) showed greater growth inhibitory activity in normal colon organoids than in CRC organoids. This was likely due to the faster proliferation of normal colon organoids. Despite this bias, the BET bromodomain protein inhibitor (+)-JQ1 (CAS number: 1268524-70-4) was shown to suppress organoid growth in a cancer-specific manner.
[0108] Figure 12 shows the IC value of (+)-JQ1 on normal colon organoids (n=6) and CRC organoids (n=15). 50 12 is a graph showing the results. In FIG. 12, each dot represents one type of organoid line. The bars in the graph represent the mean ± standard deviation. "*" indicates P = 1.38 × 10 -3 indicates that there is a significant difference.
[0109] Figure 13 shows representative micrographs showing the response of normal colon organoids and CRC organoids to (+)-JQ1. The scale bar is 500 μm. In Figure 13, "Normal" indicates the results for normal colon organoids, and "CRC7" and "CRC17a" indicate the names of the CRC organoid lines.
[0110] These results demonstrate the utility of using normal organoids alongside cancer organoids for the discovery of potential therapeutics.
[0111] [Example 5] All animal experiments were conducted with the approval of the Keio University School of Medicine Experimental Animal Center. To verify whether the results of HTS using in vitro cultured organoids were the same as those in vivo, CRC organoids were xenotransplanted into nude mice.
[0112] CRC organoids were cultured in the same manner as in Example 1. The CRC organoids obtained by suspension culture were centrifuged, and the pellet was suspended in cold Matrigel. 0.2 mL (1 × 10 6The cells (cells / injection) were injected subcutaneously into four sites on the left and right sides of nude mice and transplanted.
[0113] The tumor volume was measured over time using an electronic caliber. 3 After reaching a tumor mass of 1000 mg / kg, cetuximab (40 mg / kg, Merck) was injected intraperitoneally every 3 days for 7 doses. Nab-paclitaxel (20 mg / kg, Taiho Pharmaceutical Co., Ltd.) was also injected intravenously twice a week for 6 doses. Further tumor volume measurements confirmed that the in vivo drug efficacy results were in good agreement with the in vitro HTS results.
[0114] According to the present invention, a technique for efficiently mass-culturing organoids can be provided, regardless of whether they are derived from normal tissue or tumor tissue. The present invention enables HTS screening of drugs that have minimal side effects on normal tissue and are specifically effective against tumor tissue.
Claims
1. A method for producing an organoid, comprising: Dissociating biological tissue; The dissociated biological tissue is cultured in a suspension in a medium to form organoids. The medium is substantially free of a p38 inhibitor and contains the following components (i) to (iv): (i) 0.1 to 10% by volume of extracellular matrix (ii) Insulin-like growth factor 1 (IGF-1) (iii) Fibroblast growth factor 2 (FGF-2) (iv) at least one selected from the group consisting of Wnt agonists, bone morphogenetic protein (BMP) inhibitors, transforming growth factor-β (TGF-β) inhibitors, and epidermal growth factor (EGF) inhibitors;
2. A method for producing an organoid, comprising: Dissociating biological tissue; The dissociated biological tissue is cultured in a suspension in a medium to form organoids. The medium is substantially free of a p38 inhibitor and contains the following components (i) and (iv): (i) 0.1 to 10% by volume of extracellular matrix (iv) at least one selected from the group consisting of a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and an EGF
3. A method for producing an organoid, comprising: Dissociating biological tissue; The dissociated biological tissue is cultured in a suspension in a medium to form organoids. The medium is substantially free of a p38 inhibitor and a growth factor, and contains 0.1 to 10 volume % of an extracellular matrix.
4. The method according to any one of claims 1 to 3, wherein the suspension culture is carried out while stirring the medium.
5. The method according to any one of claims 1 to 3, wherein the biological tissue includes normal tissue and tumor tissue.
6. A manufacturing method described in any one of claims 1 to 3, wherein the dissociated biological tissue is a single cell.
7. The method according to any one of claims 1 to 3, wherein the Wnt agonist is a Wnt protein and R-spondin.
8. The method of claim 7, wherein the Wnt protein is in a complex with afamin.
9. A method for screening an anticancer drug, comprising the steps of: A step of floating-culturing normal tissue-derived organoids and tumor tissue-derived organoids in a medium in the presence of a test substance; Evaluating the effect of the test substance on the normal tissue-derived organoid and the tumor tissue-derived organoid; A test substance that has few side effects on the normal tissue-derived organoids and inhibits the proliferation of the tumor tissue-derived organoids is shown to be an anticancer drug effective against the tumor tissue, The medium is substantially free of a p38 inhibitor and contains the following components (i) to (iv): (i) 0.1 to 10% by volume of extracellular matrix (ii) IGF-1 (iii) FGF-2 (iv) at least one selected from the group consisting of a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and an EGF
10. The normal tissue-derived organoid, Dissociating biological tissue that is normal tissue; The dissociated biological tissue is cultured in a suspension in a medium to form organoids. The method of screening according to claim 9, wherein the medium is an organoid produced by a production method that is substantially free of a p38 inhibitor and includes the following components (i) to (iv): (i) 0.1 to 10% by volume of extracellular matrix (ii) IGF-1 (iii) FGF-2 (iv) at least one selected from the group consisting of a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and an EGF
11. A culture medium for producing normal tissue organoids, which is substantially free of p38 inhibitors and comprises the following components (i) to (iv): (i) 0.1 to 10% by volume of extracellular matrix (ii) IGF-1 (iii) FGF-2 (iv) at least one selected from the group consisting of a Wnt agonist, a BMP inhibitor, a TGF-β inhibitor, and an EGF
